

Efficacy of Placental Membrane Dressings in Accelerating Diabetic Foot Healing

NCT07326553

Status	RECRUITING
Phase	Phase 4
Sponsor	BioXTek
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (14)

- Patient has signed the informed consent form.
 - Male or female patient at least 18 years of age or older, as of the date of the screening visit.
 - Confirmed diagnosis of Type 1 or Type 2 DM.
 - Has a DFU that is located below the malleoli ranging in size from 1.0 cm² to 20.0 cm², post debridement, when measured by the investigator staff at the screening visit using the eKare device.
 - The DFU has been present for e4 weeks and d12 months.
- ... and 9 more (see full listing online)

Exclusion (16)

- Hemoglobin A1c (HbA1c) level is \geq 10%.
 - Chronic oral steroid use of \geq 7.5 mg daily within the previous 30 days preceding screening.
 - Chronic oral or parenteral corticosteroids, or any cytotoxic agents within the previous 30 days preceding screening.
 - Has tested positive for Human Immunodeficiency Virus (HIV) or has Acquired Immune Deficiency Syndrome (AIDS).
 - Has malignancy or history of cancer in 5 years preceding the screening visit other than non- melanoma skin cancer.
- ... and 11 more (see full listing online)

Locations (2 total)

Axsendo, Phoenix, Arizona, United States
Axsendo Clinical Research, Houston, Texas, United States